Meeting
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Authors
Elizabeth Ann Mittendorf
The University of Texas MD Anderson Cancer Center, Houston, TX
Elizabeth Ann Mittendorf , Erika J Schneble , Sonia A. Perez , James T Symanowski , Ritesh Patil , Timothy J. Vreeland , John S. Berry IV, Alfred F Trappey III, Guy T. Clifton , Eric von Hofe , Alexandros Ardavanis , Sathibalan Ponniah , Nathan M. Shumway , Michael Papamichail , George Earl Peoples
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00524277
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 638)
DOI
10.1200/jco.2014.32.15_suppl.638
Abstract #
638
Poster Bd #
102
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
First Author: Kaitlin M. Peace
Poster
2012 Breast Cancer Symposium
Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer.
First Author: Elizabeth Mittendorf
Poster
2019 ASCO Annual Meeting
Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.
First Author: Jessica Campf
Poster
2015 ASCO Annual Meeting
Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
First Author: Julia M. Greene